CTOs on the Move

Kinnate

www.kinnate.com

 
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kinnate.com
  • 12830 El Camino Real Suite 150
    San Diego, CA USA 92130
  • Phone: 858.299.4699

Executives

Name Title Contact Details

Funding

Kinnate raised $74.5M on 12/19/2019
Kinnate raised $98M on 08/26/2020

Similar Companies

New Horizon Agency Group

New Horizon Agency Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cresilon Inc

Recognizing the importance of managing a traumatic bleed quickly and effectively, Joe Landolina and Isaac Miller founded Cresilon, Inc. based on the hemostatic plant-based gel technology Joe invented while experimenting in the lab. Cresilon has since grown into a biotechnology company headquartered in Brooklyn, New York, commercializing our medical device technology in the animal health, trauma care, and surgical markets.

i-novel Medical

i-novel Medical is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clemson University Biomedical Engineering Innovation Campus

The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.

Kira Pharmaceuticals

Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases